Over a month ago |
Hot Stocks
|
Moleculin Biotech… Moleculin Biotech commenced dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19. The Phase 1a, first-in-human, overlapping Single and Multiple ascending dose will investigate the effects of WP1122 administered as an oral solution in healthy human volunteers in the U.K. This study in healthy volunteers will explore safety and PK, and subsequent antiviral clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. Moleculin is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur. ShowHide Related Items >><< - 05/10/22
- Moleculin Biotech receives approval from UK MHRA for Phase 1a study of WP1122
- 05/05/22
- Moleculin Biotech's Phase 1/2 Annamycin study in AML allowed to proceed
- 04/21/22
- Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate
- 04/14/22
- Moleculin Biotech announces corporate rebranding, launch of new website
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
|
Hot Stocks
|
Moleculin Biotech… Moleculin Biotech announced that it has received approval from the UK MHRA to proceed with a first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, or MB-301. The approval follows Moleculin's having submitted a protocol amendment allowing for a higher ratio of diluting excipients to drug substance to facilitate a faster and simpler mixing procedure before drug administration. WP1122, the Company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, currently being developed for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. The mechanism of action of 2-DG includes both the inhibition of glycolysis and the disruption of glycosylation, two processes that are important to both viral activity and tumor development. WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile, and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. WP1122 has also been shown to have a more potent antiviral effect than 2-DG against SARS-CoV-2 in MRC-5 cells in culture. ShowHide Related Items >><< - 05/05/22
- Moleculin Biotech's Phase 1/2 Annamycin study in AML allowed to proceed
- 04/21/22
- Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate
- 04/14/22
- Moleculin Biotech announces corporate rebranding, launch of new website
- 04/08/22
- Moleculin Biotech to present preclinical annamycin data at AACR
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Hot Stocks
|
Moleculin Biotech has… Moleculin Biotech has received allowance from the Polish Department of Registration of Medicinal Products - URPL -, as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin in combination with Cytarabine ) in the treatment of subjects with acute myeloid leukemia - AML - who are refractory to or relapsed after induction therapy. The Phase 1/2 L-ANN /ARA-C combination trial, an open label trial, builds on the safety and dosage data from the two successfully concluded single agent Annamycin AML Phase 1 trials in the U.S. and Europe and the preclinical data discussed below. The study is expected to commence patient enrollment in the first half of 2022. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines. ShowHide Related Items >><< - 04/21/22
- Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate
- 04/14/22
- Moleculin Biotech announces corporate rebranding, launch of new website
- 04/08/22
- Moleculin Biotech to present preclinical annamycin data at AACR
- 03/25/22
- Moleculin Biotech says cash sufficient to fund operations into 2024
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Hot Stocks
|
Moleculin Biotech… Moleculin Biotech announced that the FDA is allowing the company's Investigational New Drug application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma. WP1066 is the company's flagship Immune/Transcription Modulator designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors. These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation. WP1066 is currently being evaluated for the treatment of pediatric brain tumors. The company has received Orphan Drug Designation for WP1066 for the treatment of brain tumors, as well as Rare Pediatric Disease designation for three other pediatric indications. Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme. Glioma is a common type of tumor originating in the brain. About 33% of all brain tumors are gliomas. ShowHide Related Items >><< - 04/14/22
- Moleculin Biotech announces corporate rebranding, launch of new website
- 04/08/22
- Moleculin Biotech to present preclinical annamycin data at AACR
- 03/25/22
- Moleculin Biotech says cash sufficient to fund operations into 2024
- 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Hot Stocks
|
Moleculin Biotech… Moleculin Biotech announced the launch its new corporate branding and website www.moleculin.com. "As we drive clinical development across our broad portfolio of drug candidates, expand our growing body of clinical data and build value among all stakeholders, we believed it was an important step to refresh our corporate branding identity and website to align with the true potential and vision we have for Moleculin. We are wholeheartedly committed to potentially solving some of the toughest challenges and importantly, bringing better treatments to patients where there remains unmet medical need. The work completed and data demonstrated to-date bolsters our confidence as we believe we can successfully execute on a number of key clinical and regulatory milestones that will be instrumental in establishing a clear path to approval and commercialization of Annamycin. I am excited for this evolution of Moleculin and to take another step forward towards the future of this exciting company," commented Walter Klemp, Chairman and CEO of Moleculin. ShowHide Related Items >><< - 04/08/22
- Moleculin Biotech to present preclinical annamycin data at AACR
- 03/25/22
- Moleculin Biotech says cash sufficient to fund operations into 2024
- 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 01/25/22
- WPD Pharmaceuticals enters amended sublicense agreement with Moleculin Biotech
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 04/14/21 Roth Capital
- Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Hot Stocks
|
Moleculin Biotech… Moleculin Biotech announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting 2022, being held April 8-13. Annamycin exhibited robust antitumor activity in both models. In the lung metastasis model, a dose-dependent delay in the tumor progression was visualized by both BLI and CT scan in the Annamycin treated group. The delay correlated with 272% extension of survival in the group receiving 6 mg/kg Annamycin and 234% for the animals dosed with Annamycin at 4 mg/kg. In the liver metastasis model, all vehicle-treated mice showed massive tumors in the liver and peritoneal cavity as monitored by BLI and MRI. In the vehicle group, 13/14 died or were euthanized by 35d. Yet, no tumors were detected by BLI or MRI in Annamycin treated mice as of 44d and 0/14 mice died. This indicates a highly significant extension of survival, the company said. "We continue to be encouraged by the growing body of robust preclinical and human clinical data demonstrated by Annamycin. The positive results seen in these preclinical models provide added confidence in the potential follow-on development opportunities we believe Annamycin holds. While metastatic colorectal cancer is not an immediate area of focus for us, this data set continues to provide valuable insight as we advance its clinical development for the treatment of highly resistant tumors," commented Walter Klemp, Chairman and CEO of Moleculin. ShowHide Related Items >><< - 03/25/22
- Moleculin Biotech says cash sufficient to fund operations into 2024
- 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 01/25/22
- WPD Pharmaceuticals enters amended sublicense agreement with Moleculin Biotech
- 01/18/22
- Moleculin Biotech announces updated safety data for Annamycin in Phase 1 trials
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 04/14/21 Roth Capital
- Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Over a quarter ago |
Hot Stocks
|
The company ended the… The company ended the year with $70.9M of cash. The company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, into 2024. "Over the course of 2021, we have made significant progress across multiple fronts. As we look ahead, I believe we are well positioned for an exciting 2022 with a number of clinical and regulatory milestones expected throughout the year," commented Walter Klemp, Chairman and CEO of Moleculin. "Our Annamycin development programs in STS lung mets and AML continue to progress and we remain encouraged by the data seen to date. Additionally, with the necessary regulatory approvals received, we are advancing parallel development of WP1122 for the treatment of COVID-19 and GBM. With our growing body of encouraging clinical data and our strong financing position, we remain laser focused on executing our initiatives, driving value for all stakeholders, and importantly, addressing unmet needs for people with highly resistant tumors and viruses." ShowHide Related Items >><< - 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 01/25/22
- WPD Pharmaceuticals enters amended sublicense agreement with Moleculin Biotech
- 01/18/22
- Moleculin Biotech announces updated safety data for Annamycin in Phase 1 trials
- 12/27/21
- Moleculin announce preliminary interim results in Phase 1b/2 trial of annamycin
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 04/14/21 Roth Capital
- Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
|
Conference/Events
|
34th Annual ROTH… 34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link ShowHide Related Items >><< - 01/20/22
- Beauty Health announces Andrew Stanleick as President and CEO
- 11/09/21
- Beauty Health CEO Clint Carnell to leave company
- 03/10/22
- Sintx Technologies awarded Phase 1 grant $300,000 from NIH
- 02/23/22
- Sintx Technologies announces milestones in development of antipathogenic fabrics
- 12/31/21
- Sintx Technologies CSO Bryan McEntire to retire
- 12/08/21
- Sintx Technologies provides year-end business update
- 01/04/22
- P3 Health Partners expands to California, closes two acquisitions
PBLA Panbela Therapeutics - 02/22/22
- Panbela Therapeutics Inc trading resumes
- 02/22/22
- Panbela Therapeutics to acquire Cancer Prevention Pharmaceuticals
- 02/22/22
- Panbela Therapeutics Inc trading halted, news pending
- 01/26/22
- Panbela Therapeutics initiates Phase 2 trial of SBP-101
- 01/19/22
- Marker Therapeutics confirms FDA Orphan Drug designation of MT-601
- 01/18/22
- Marker Therapeutics treatment of pancreatic cancer granted orphan status
MNPR Monopar Therapeutics - 02/15/22
- Monopar Therapeutics announces clinical, preclinical program updates
- 12/08/21
- Monopar dosing of camsirubicin to higher levels than previous trials
- 11/12/21
- Monopar Therapeutics plans to raise additional funds and/or engage partner
- 10/27/21
- Monopar announces first patient dosed in Phase 1b trial on camsirubicin
- 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 01/25/22
- WPD Pharmaceuticals enters amended sublicense agreement with Moleculin Biotech
- 01/18/22
- Moleculin Biotech announces updated safety data for Annamycin in Phase 1 trials
- 12/27/21
- Moleculin announce preliminary interim results in Phase 1b/2 trial of annamycin
- 02/24/22
- LeMaitre announces $20M share repurchase authorization
- 03/10/22
- aTyr Pharma to initiate registrational study of efzofitimod in Q3
- 01/13/22
- aTyr Pharma announces USAN, INN selected efzofitimod as name for ATYR1923
- 01/06/22
- aTyr Pharma announces FDA orphan drug designation for ATYR1923
- 01/05/22
- aTyr Pharma treatment of sarcoidosis granted FDA orphan designation
- 12/22/21
- Ligand partner CStone gets China approval for Cejemly to treat NSCLC
- 12/21/21
- Ligand, GlaxoSmithKline expand collaboration and license agreement
- 11/10/21
- Ligand announces plans for OmniAb to become standalone public company
- 10/21/21
- Ligand, CR Double-Crane in pact to make COVID-19 therapeutic with BEPro tech
- 03/04/22
- Lannett receives notice of non-compliance from NYSE
- 03/04/22
- Lannett to sell liquid drug manufacturing facility in New York for $10.5M
- 01/21/22
- Lannett announces completion of FDA safety review of insulin glargine IND
- 12/20/21
- Lannett submits biosimilar insulin glargine IND to FDA
- 02/23/22
- KemPharm expects to submit KP1077 IND by mid-2022 following FDA meeting
- 01/19/22
- KemPharm issues letter to shareholders regarding clinical development strategy
- 01/11/22
- KemPharm announces research on SDX to be presented at APSARD 2022
- 12/20/21
- KemPharm announces authorization of $50M share repurchase program
- 03/07/22
- KalVista inititates Phase 3 KONFIDENT clinical trial evaluating KVD900
- 01/24/22
- KalVista publishes KVD900 data in JACI
- 11/10/21
- KalVista provides update on clinical trial progress for KVD900
- 11/08/21
- KalVista announces data at ACAAI from Phase 2 data for KVD900
- 02/07/22
- iRadimed announces $1.00 per share special cash dividend
- 02/03/22
- INVO Bioscience regains U.S. commercialization rights to INVOcell technology
- 12/16/21
- INVO Bioscience partners with Ovoclinic in Spain for INVOcell commercialization
- 12/01/21
- INVO Bioscience obtains regulatory Approval for INVOcell in Thailand
- 11/08/21
- INVO Bioscience regains full U.S. commercialization rights for INVOcell device
INM InMed Pharmaceuticals - 02/15/22
- InMed Pharmaceuticals appoints VP of Sales, Marketing for BayMedica
- 01/19/22
- InMed Pharmaceuticals launches CBT, expanding rare cannabinoid portfolio
- 01/05/22
- InMed issues annual letter to shareholders on 2021 review, 2022 outlook
- 12/20/21
- InMed Pharmaceuticals announces article on use of CBN to treat Glaucoma
INDP Indaptus Therapeutics - 01/03/22
- Indaptus Therapeutics announces appointment of Boyan Litchev as CMO
- 12/01/21
- Indaptus Therapeutics appoints Mark Gilbert to board of directors
- 02/23/22
- GlycoMimetics names Bruce Johnson CCO
- 11/23/21
- GlycoMimetics says Apollomics doses first patient in Ph3 APL-106 trial in China
- 11/15/21
- GlycoMimetics completes enrollment in uproleselan trial
- 09/27/21
- GlycoMimetics to study uproleselan in patients with COVID-19 pneumonia
FWBI First Wave BioPharma - 03/03/22
- First Wave BioPharma announces poster presentation at DDW 2022
- 03/01/22
- First Wave BioPharma appoints Sarah Romano as Chief Financial Officer
- 02/28/22
- First Wave BioPharma announces $9M registered direct offering
- 01/13/22
- First Wave BioPharma provides update on Adrulipase clinical program
- 03/03/22
- Field Trip Health and Cerebral partner for end-to-end mental health care
- 01/11/22
- Field Trip Health trading resumes
- 01/11/22
- Field Trip receives notice of allowance for patent application covering FT-104
- 01/11/22
- Field Trip Health trading halted, news pending
- 12/16/21
- Fortress Biotech announces initiation of Phase 2 clinical trial of Triplex
- 12/07/21
- Fortress, Cyprium, Sentynl initiate rolling submission of NDA for CUTX-101
- 11/29/21
- Journey Medical announces expanded board of directors
- 11/12/21
- Journey Medical prices $35.2M IPO
- 01/27/22
- Ensysce Biosciences announces results of special meeting of stockholders
- 01/10/22
- Ensysce Biosciences announces first cohort dosing in BE study of TAAP opioid
- 01/04/22
- Ensysce Biosciences complete part A of MAD/BE trial for PF614
- 12/15/21
- Ensysce Biosciences enrolls first patient in PF614-MPAR study
- 02/22/22
- Delcath Systems moves to direct sales, marketing model for CHEMOSAT
- 02/03/22
- Delcath Systems announces results from Chemostat system study
- 01/25/22
- Delcath Systems appoints David Hoffman as general counsel, CCO
- 12/02/21
- Delcath Systems Inc trading resumes
- 12/07/21
- Dare Bioscience Inc trading resumes
- 12/07/21
- Dare announces FDA approval of XACIATO vaginal gel for bacterial vaginosis
- 12/07/21
- FDA approves Dare Bioscience's Xaciato vaginal gel
- 12/07/21
- Dare Bioscience Inc trading halted, news pending
- 03/10/22
- Cocrystal Pharma initiates enrollment in Phase 1 study of CC-42344
- 01/27/22
- Cocrystal selects two antiviral drug candidates for COVID-19 oral drug program
- 01/06/22
- Cocrystal Pharma receives FDA guidance on CDI-45205
- 12/22/21
- Cocrystal Pharma's announce results on COVID-19 oral inhibitors against omicron
- 01/19/22
- Compass Pathways announces results from survey conducted with Sermo on TRD
- 01/04/22
- Compass Pathways announces results from phase I study on COMP360
- 12/17/21
- Compass Pathways to be added to Nasdaq Biotechnology Index
- 12/16/21
- Compass Pathways appoints Owens as CLO, CBO Wilde moving to advisory role
- 03/14/22
- Clene presents updated clinical data from Phase 2 RESCUE-ALS, REPAIR trials
- 03/11/22
- Clene provides update on upcoming trial results
- 03/11/22
- Clene see cash funding operations into Q2 of 2023
- 02/24/22
- Clene presents data from two Phase 2 MS trials
- 02/14/22
- Axcella Health receives fast track designation from FDA for AXA1125
- 02/07/22
- Axcella Health appoints Robert Crane as CFO
- 01/18/22
- Axcella poised for 'transformational year,' CEO Hinshaw says
- 01/18/22
- Axcella's Hinshaw has seen no major COVID-related impacts to trials
ATNM Actinium Pharmaceuticals - 02/22/22
- Actinium Pharmaceuticals and Aveo Oncology to co-develop radiotherapy
- 01/05/22
- Actinium Pharmaceuticals, EpicentRx announce research collaboration
- 12/14/21
- Actinium reports data from Actimab-A and CLAG-M Phase 1 combination trial
- 12/14/21
- Actinium presents data from Phase 1 portion of Actimab-A and venetoclax trial
- 02/01/22
- IntelGenx receives third loan tranche from Atai Life Sciences
- 01/27/22
- Atai Life Sciences to partner with Dalriada
- 01/12/22
- atai Life Sciences' IND for PCN-101 approved by FDA
- 12/15/21
- Atai Life Sciences: Apeiron, others to extend lock-up for pre-IPO shares
ATNM Actinium Pharmaceuticals - 09/15/21 Alliance Global Partners
- Actinium price target lowered to $20 from $25 at Alliance Global Partners
- 08/03/21 H.C. Wainwright
- Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
- 04/06/21 William Blair
- Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences - 02/01/22 H.C. Wainwright
- Awakn Life Sciences initiated with a Buy at H.C. Wainwright
- 10/12/21 Noble Capital
- Axcella Health initiated with an Outperform at Noble Capital
- 09/22/21 Goldman Sachs
- Axcella Health downgraded to Neutral from Buy at Goldman Sachs
- 07/30/21 JPMorgan
- Axcella downgraded to Underweight on lack of catalysts at JPMorgan
- 07/30/21 JPMorgan
- Axcella Health downgraded to Underweight from Neutral at JPMorgan
- 11/03/21 Cantor Fitzgerald
- Clene price target lowered to $15 from $24 at Cantor Fitzgerald
- 11/02/21 Roth Capital
- Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
- 11/02/21 Benchmark
- Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
- 05/20/21 Maxim
- Clene initiated with a Buy at Maxim
- 06/15/21 H.C. Wainwright
- Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
- 02/17/22 Stifel
- Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
- 11/22/21 H.C. Wainwright
- Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
- 11/18/21 Stifel
- Field Trip Health price target raised to C$11.50 from C$10 at Stifel
- 09/01/21 H.C. Wainwright
- Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma - 12/07/21 Maxim
- First Wave BioPharma downgraded to Hold from Buy at Maxim
- 12/07/21 Maxim
- First Wave BioPharma downgraded to Hold from Buy at Maxim
- 10/26/21 Roth Capital
- Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
- 09/29/21 H.C. Wainwright
- H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
- 06/17/21 B. Riley
- Fortress Biotech price target lowered to $8 from $9 at B. Riley
- 04/14/21 B. Riley
- Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
- 02/28/22 Canaccord
- Compass Pathways price target lowered to $78 from $80 at Canaccord
- 11/11/21 Roth Capital
- Atai Life Sciences initiated with a Buy at Roth Capital
- 11/09/21 Citi
- Citi says Compass Pathways selloff overdone, ups price target to $70
- 11/09/21 Cantor Fitzgerald
- Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
- 01/19/22 Brookline
- Dare Bioscience assumed with a Buy at Brookline
- 07/12/21 Roth Capital
- Roth adds more 'SMID-cap' names to second half top picks
- 07/12/21 Roth Capital
- Dare Bioscience NIH agreement should offset costs, says Roth Capital
- 07/07/21 Roth Capital
- Dare Bioscience grant reflects large market need, says Roth Capital
- 12/10/21 H.C. Wainwright
- Delcath Systems initiated with a Buy at H.C. Wainwright
- 06/08/21 Roth Capital
- Delcath Systems data suggest approvability, says Roth Capital
- 04/06/21 Roth Capital
- Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition - 11/12/21
- Fly Intel: Top five analyst upgrades
- 11/12/21 Jefferies
- GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
- 11/12/21 Jefferies
- GlycoMimetics upgraded to Buy from Hold at Jefferies
- 09/27/21 Roth Capital
- GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
- 11/10/21 Roth Capital
- KalVista FDA meeting feedback 'quite positive,' says Roth Capital
- 08/23/21 Roth Capital
- KalVista could take 'substantial' share of HAE market, says Roth Capital
- 04/20/21 Roth Capital
- KalVista selloff seems overdone after clinical hold, says Roth Capital
- 01/31/22 H.C. Wainwright
- KemPharm upgraded to Buy from Neutral at H.C. Wainwright
- 05/26/21 Roth Capital
- Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
- 02/25/22 Barrington
- LeMaitre price target lowered to $54 from $62 at Barrington
- 09/16/21
- Fly Intel: Top five analyst initiations
- 09/16/21 Jefferies
- Jefferies starts LeMaitre at Buy on ArteGraft upside potential
- 09/16/21 Jefferies
- LeMaitre initiated with a Buy at Jefferies
- 02/22/22 Benchmark
- Ligand price target lowered to $130 from $180 at Benchmark
- 02/18/22 Barclays
- Ligand price target lowered to $165 from $185 at Barclays
- 09/22/21 Barclays
- Ligand price target raised to $180 from $174 at Barclays
- 08/25/21 H.C. Wainwright
- Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
- 08/05/21 Piper Sandler
- Lumos shares trading below cash, says Piper Sandler
- 07/22/21 Roth Capital
- Lumos Pharma price target lowered to $35 from $51 at Roth Capital
- 07/21/21 Piper Sandler
- Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
- 07/21/21 H.C. Wainwright
- Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
- 02/17/22 Roth Capital
- Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
- 02/17/22 Piper Sandler
- Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
- 03/25/21 Piper Sandler
- Marker Therapeutics initiated with an Overweight at Piper Sandler
- 03/19/21
- Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics - 02/23/22 Craig-Hallum
- Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
- 06/28/21 Roth Capital
- Panbela Therapeutics initiated with a Buy at Roth Capital
- 01/04/22 William Blair
- P3 Health Partners initiated with an Outperform at William Blair
- 12/28/21 Lake Street
- Lake Street names 18 small cap best ideas for 2022
- 03/14/22 Benchmark
- Beauty Health price target raised to $23 from $18 at Benchmark
- 03/11/22 JPMorgan
- Beauty Health initiated with an Overweight at JPMorgan
- 01/07/22 William Blair
- William Blair starts Beauty Health with Outperform, sees 20%-plus growth
- 01/07/22 William Blair
- Beauty Health initiated with an Outperform at William Blair
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 04/14/21 Roth Capital
- Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics - 11/01/21 H.C. Wainwright
- Monopar Therapeutics initiated with a Buy at H.C. Wainwright
- 10/19/21 Roth Capital
- Roth Capital bullish on Monopar Therapeutics after competitor trial fails
- 03/02/22 Stifel
- Iridex transferred with Buy rating at Stifel
- 11/02/21 Roth Capital
- iRadimed price target raised to $42 from $36 at Roth Capital
- 01/19/22 Maxim
- INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals - 11/29/21 H.C. Wainwright
- InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics - 01/31/22 H.C. Wainwright
- Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
- 10/19/21
- Fly Intel: Top five analyst upgrades
- 10/19/21 Maxim
- Indaptus Therapeutics upgraded to Buy from Hold at Maxim
- 10/19/21 Maxim
- Indaptus Therapeutics upgraded to Buy from Hold at Maxim
- 11/30/21 Lake Street
- Ensysce Biosciences initiated with a Buy at Lake Street
- 11/11/21 Roth Capital
- aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
- 10/12/21 RBC Capital
- aTyr Pharma initiated with an Outperform at RBC Capital
- 09/21/21 Piper Sandler
- aTyr Pharma initiated with an Overweight at Piper Sandler
- 09/14/21 Oppenheimer
- aTyr Pharma price target raised to $20 from $14 at Oppenheimer
- 11/30/21
- Fly Intel: Top five analyst initiations
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 11/22/21 Canaccord
- Atai Life Sciences weakness a buying opportunity, says Canaccord
- 02/22/22
- Beauty Health sees FY22 revenue $320M-$330M, consensus $314M
- 02/22/22
- Beauty Health reports Q4 EPS (12c), consensus (2c)
- 01/10/22
- Beauty Health sees FY21 revenue $245M -$255M, consensus $231.03M
- 11/09/21
- Beauty Health raises FY21 revenue view to $245M-$255M from $230M-$240M
- 03/09/22
- P3 Health Partners sees 2022 revenue $950M-$1B, consensus $820.04M
- 03/09/22
- P3 Health Partners sees 2021 revenue $642M, consensus $630.57M
- 03/09/22
- P3 Health Partners sees Q4 revenue $183M, consensus $171.07M
- 11/10/21
- Marker Therapeutics reports Q3 EPS (15c), consensus (13c)
MNPR Monopar Therapeutics - 11/12/21
- Monopar Therapeutics reports Q3 EPS (20c), consensus (21c)
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
- 03/10/22
- Lumos Pharma reports FY21 EPS ($3.65), consensus ($3.89)
- 11/03/21
- Lumos Pharma reports Q3 EPS (90c), consensus ($1.07)
- 02/24/22
- LeMaitre reports Q4 EPS 28c, consensus 31c
- 10/28/21
- LeMaitre sees FY21 EPS $1.26-$1.31, consensus $1.35
- 10/28/21
- LeMaitre sees Q4 EPS 29c-34c, consensus 34c
- 10/28/21
- LeMaitre reports Q3 EPS 30c, consensus 32c
- 03/14/22
- aTyr Pharma reports Q4 EPS (31c), consensus (28c)
- 11/10/21
- aTyr Pharma reports Q3 EPS (42c), consensus (60c)
- 02/17/22
- Ligand sees FY22 revenue $147M-$172M, consensus $189.9M
- 02/17/22
- Ligand reports Q4 EPS $1.80, consensus $1.37
- 11/09/21
- Ligand reaffirms FY21 EPS view $5.80-$6.05, consensus $5.93
- 11/09/21
- Ligand reports Q3 EPS $1.58, consensus $1.04
- 02/03/22
- Lannett lowers FY22 revenue view to $335M-$360M from $370M-$400M
- 02/03/22
- Lannett reports Q2 EPS (39c), consensus (32c)
- 11/03/21
- Lannett cuts FY21 adjusted revenue view $370M-$400M from $400M-$440M
- 11/03/21
- Lannett reports Q1 adjusted EPS (27c), consensus (24c)
- 03/10/22
- KalVista reports Q3 EPS (92c), consensus (93c)
- 12/09/21
- KalVista reports Q2 EPS (80c), consensus (79c)
- 02/04/22
- iRadimed sees 2022 adjusted EPS 91c-$1.01, two est. 83c
- 02/04/22
- iRadimed sees Q1 adjusted EPS 20c-21c
- 02/04/22
- iRadimed reports Q4 adjusted EPS 33c, two est. 21c
- 10/29/21
- iRadimed raises 2021 adjusted EPS view 70c-71c from 60c-62c, two est. 62c
- 01/11/22
- Iridex sees FY21 revenue $53.7M-$53.9M, two estimates $52.64M
- 01/11/22
- Iridex reports preliminary Q4 revenue $15.1M-$15.3M, two estimates $14.01M
- 11/15/21
- INVO Bioscience reports Q3 EPS (24c), two estimates (20c)
INM InMed Pharmaceuticals - 11/10/21
- InMed Pharmaceuticals reports Q1 EPS (25c), one estimate (35c)
- 09/24/21
- InMed Pharmaceuticals reports 2021 EPS ($1.52) vs. ($1.71) last year.
INDP Indaptus Therapeutics - 11/15/21
- Indaptus Therapeutics reports Q3 EPS (81c) vs. (79c) a year ago
- 03/03/22
- GlycoMimetics reports Q4 EPS (33c), consensus (34c)
- 11/02/21
- GlycoMimetics reports Q3 EPS (34c), consensus (32c)
- 02/15/22
- Field Trip Health reports Q3 EPS (26c), consensus (16c)
- 11/15/21
- Field Trip Health reports Q2 EPS (23c), consensus (15c)
- 11/15/21
- Fortress Biotech reports Q3 EPS (26c), consensus (8c)
- 11/09/21
- Delcath Systems reports Q3 EPS (94c), consensus ($1.08)
- 11/10/21
- Dare Bioscience reports Q3 EPS (18c), consensus (13c)
- 11/15/21
- Cocrystal Pharma reports Q3 EPS (4c), consensus (4c)
- 02/24/22
- Compass Pathways reports Q4 EPS (61c), consensus (50c)
- 11/09/21
- Compass Pathways reports Q3 EPS (38c), consensus (49c)
- 03/11/22
- Clene reports 2021 EPS (16c), consensus (17c)
- 11/09/21
- Clene reports Q3 EPS 42c, consensus (20c)
- 11/10/21
- Axcella Health reports Q3 EPS (41c), consensus (46c)
- 11/15/21
- Atai Life Sciences reports Q3 EPS (21c), consensus (20c)
|
Conference/Events
|
34th Annual ROTH… 34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link ShowHide Related Items >><< - $15.75 /
-1.915 (-10.84%) - 01/20/22
- Beauty Health announces Andrew Stanleick as President and CEO
- 11/09/21
- Beauty Health CEO Clint Carnell to leave company
- 03/10/22
- Sintx Technologies awarded Phase 1 grant $300,000 from NIH
- 02/23/22
- Sintx Technologies announces milestones in development of antipathogenic fabrics
- 12/31/21
- Sintx Technologies CSO Bryan McEntire to retire
- 12/08/21
- Sintx Technologies provides year-end business update
- 01/04/22
- P3 Health Partners expands to California, closes two acquisitions
PBLA Panbela Therapeutics - 02/22/22
- Panbela Therapeutics Inc trading resumes
- 02/22/22
- Panbela Therapeutics to acquire Cancer Prevention Pharmaceuticals
- 02/22/22
- Panbela Therapeutics Inc trading halted, news pending
- 01/26/22
- Panbela Therapeutics initiates Phase 2 trial of SBP-101
- 01/19/22
- Marker Therapeutics confirms FDA Orphan Drug designation of MT-601
- 01/18/22
- Marker Therapeutics treatment of pancreatic cancer granted orphan status
MNPR Monopar Therapeutics - 02/15/22
- Monopar Therapeutics announces clinical, preclinical program updates
- 12/08/21
- Monopar dosing of camsirubicin to higher levels than previous trials
- 11/12/21
- Monopar Therapeutics plans to raise additional funds and/or engage partner
- 10/27/21
- Monopar announces first patient dosed in Phase 1b trial on camsirubicin
- 02/14/22
- Moleculin Biotech announces preliminary result from Phase 2 trial of Annamycin
- 01/25/22
- WPD Pharmaceuticals enters amended sublicense agreement with Moleculin Biotech
- 01/18/22
- Moleculin Biotech announces updated safety data for Annamycin in Phase 1 trials
- 12/27/21
- Moleculin announce preliminary interim results in Phase 1b/2 trial of annamycin
- 02/24/22
- LeMaitre announces $20M share repurchase authorization
- 03/10/22
- aTyr Pharma to initiate registrational study of efzofitimod in Q3
- 01/13/22
- aTyr Pharma announces USAN, INN selected efzofitimod as name for ATYR1923
- 01/06/22
- aTyr Pharma announces FDA orphan drug designation for ATYR1923
- 01/05/22
- aTyr Pharma treatment of sarcoidosis granted FDA orphan designation
- 12/22/21
- Ligand partner CStone gets China approval for Cejemly to treat NSCLC
- 12/21/21
- Ligand, GlaxoSmithKline expand collaboration and license agreement
- 11/10/21
- Ligand announces plans for OmniAb to become standalone public company
- 10/21/21
- Ligand, CR Double-Crane in pact to make COVID-19 therapeutic with BEPro tech
- 03/04/22
- Lannett receives notice of non-compliance from NYSE
- 03/04/22
- Lannett to sell liquid drug manufacturing facility in New York for $10.5M
- 01/21/22
- Lannett announces completion of FDA safety review of insulin glargine IND
- 12/20/21
- Lannett submits biosimilar insulin glargine IND to FDA
- 02/23/22
- KemPharm expects to submit KP1077 IND by mid-2022 following FDA meeting
- 01/19/22
- KemPharm issues letter to shareholders regarding clinical development strategy
- 01/11/22
- KemPharm announces research on SDX to be presented at APSARD 2022
- 12/20/21
- KemPharm announces authorization of $50M share repurchase program
- 03/07/22
- KalVista inititates Phase 3 KONFIDENT clinical trial evaluating KVD900
- 01/24/22
- KalVista publishes KVD900 data in JACI
- 11/10/21
- KalVista provides update on clinical trial progress for KVD900
- 11/08/21
- KalVista announces data at ACAAI from Phase 2 data for KVD900
- 02/07/22
- iRadimed announces $1.00 per share special cash dividend
- 02/03/22
- INVO Bioscience regains U.S. commercialization rights to INVOcell technology
- 12/16/21
- INVO Bioscience partners with Ovoclinic in Spain for INVOcell commercialization
- 12/01/21
- INVO Bioscience obtains regulatory Approval for INVOcell in Thailand
- 11/08/21
- INVO Bioscience regains full U.S. commercialization rights for INVOcell device
INM InMed Pharmaceuticals - 02/15/22
- InMed Pharmaceuticals appoints VP of Sales, Marketing for BayMedica
- 01/19/22
- InMed Pharmaceuticals launches CBT, expanding rare cannabinoid portfolio
- 01/05/22
- InMed issues annual letter to shareholders on 2021 review, 2022 outlook
- 12/20/21
- InMed Pharmaceuticals announces article on use of CBN to treat Glaucoma
INDP Indaptus Therapeutics - 01/03/22
- Indaptus Therapeutics announces appointment of Boyan Litchev as CMO
- 12/01/21
- Indaptus Therapeutics appoints Mark Gilbert to board of directors
- 09/15/21
- Indaptus Therapeutics receives notice of allowance for its platform technology
- 02/23/22
- GlycoMimetics names Bruce Johnson CCO
- 11/23/21
- GlycoMimetics says Apollomics doses first patient in Ph3 APL-106 trial in China
- 11/15/21
- GlycoMimetics completes enrollment in uproleselan trial
- 09/27/21
- GlycoMimetics to study uproleselan in patients with COVID-19 pneumonia
FWBI First Wave BioPharma - 03/03/22
- First Wave BioPharma announces poster presentation at DDW 2022
- 03/01/22
- First Wave BioPharma appoints Sarah Romano as Chief Financial Officer
- 02/28/22
- First Wave BioPharma announces $9M registered direct offering
- 01/13/22
- First Wave BioPharma provides update on Adrulipase clinical program
- 03/03/22
- Field Trip Health and Cerebral partner for end-to-end mental health care
- 01/11/22
- Field Trip Health trading resumes
- 01/11/22
- Field Trip receives notice of allowance for patent application covering FT-104
- 01/11/22
- Field Trip Health trading halted, news pending
- 12/16/21
- Fortress Biotech announces initiation of Phase 2 clinical trial of Triplex
- 12/07/21
- Fortress, Cyprium, Sentynl initiate rolling submission of NDA for CUTX-101
- 11/29/21
- Journey Medical announces expanded board of directors
- 11/12/21
- Journey Medical prices $35.2M IPO
- 01/27/22
- Ensysce Biosciences announces results of special meeting of stockholders
- 01/10/22
- Ensysce Biosciences announces first cohort dosing in BE study of TAAP opioid
- 01/04/22
- Ensysce Biosciences complete part A of MAD/BE trial for PF614
- 12/15/21
- Ensysce Biosciences enrolls first patient in PF614-MPAR study
- 02/22/22
- Delcath Systems moves to direct sales, marketing model for CHEMOSAT
- 02/03/22
- Delcath Systems announces results from Chemostat system study
- 01/25/22
- Delcath Systems appoints David Hoffman as general counsel, CCO
- 12/02/21
- Delcath Systems Inc trading resumes
- 12/07/21
- Dare Bioscience Inc trading resumes
- 12/07/21
- Dare announces FDA approval of XACIATO vaginal gel for bacterial vaginosis
- 12/07/21
- FDA approves Dare Bioscience's Xaciato vaginal gel
- 12/07/21
- Dare Bioscience Inc trading halted, news pending
- 03/10/22
- Cocrystal Pharma initiates enrollment in Phase 1 study of CC-42344
- 01/27/22
- Cocrystal selects two antiviral drug candidates for COVID-19 oral drug program
- 01/06/22
- Cocrystal Pharma receives FDA guidance on CDI-45205
- 12/22/21
- Cocrystal Pharma's announce results on COVID-19 oral inhibitors against omicron
- 01/19/22
- Compass Pathways announces results from survey conducted with Sermo on TRD
- 01/04/22
- Compass Pathways announces results from phase I study on COMP360
- 12/17/21
- Compass Pathways to be added to Nasdaq Biotechnology Index
- 12/16/21
- Compass Pathways appoints Owens as CLO, CBO Wilde moving to advisory role
- 03/14/22
- Clene presents updated clinical data from Phase 2 RESCUE-ALS, REPAIR trials
- 03/11/22
- Clene provides update on upcoming trial results
- 03/11/22
- Clene see cash funding operations into Q2 of 2023
- 02/24/22
- Clene presents data from two Phase 2 MS trials
- 02/14/22
- Axcella Health receives fast track designation from FDA for AXA1125
- 02/07/22
- Axcella Health appoints Robert Crane as CFO
- 01/18/22
- Axcella poised for 'transformational year,' CEO Hinshaw says
- 01/18/22
- Axcella's Hinshaw has seen no major COVID-related impacts to trials
ATNM Actinium Pharmaceuticals - 02/22/22
- Actinium Pharmaceuticals and Aveo Oncology to co-develop radiotherapy
- 01/05/22
- Actinium Pharmaceuticals, EpicentRx announce research collaboration
- 12/14/21
- Actinium reports data from Actimab-A and CLAG-M Phase 1 combination trial
- 12/14/21
- Actinium presents data from Phase 1 portion of Actimab-A and venetoclax trial
- 02/01/22
- IntelGenx receives third loan tranche from Atai Life Sciences
- 01/27/22
- Atai Life Sciences to partner with Dalriada
- 01/12/22
- atai Life Sciences' IND for PCN-101 approved by FDA
- 12/15/21
- Atai Life Sciences: Apeiron, others to extend lock-up for pre-IPO shares
ATNM Actinium Pharmaceuticals - 09/15/21 Alliance Global Partners
- Actinium price target lowered to $20 from $25 at Alliance Global Partners
- 08/03/21 H.C. Wainwright
- Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
- 04/06/21 William Blair
- Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences - 02/01/22 H.C. Wainwright
- Awakn Life Sciences initiated with a Buy at H.C. Wainwright
- 10/12/21 Noble Capital
- Axcella Health initiated with an Outperform at Noble Capital
- 09/22/21 Goldman Sachs
- Axcella Health downgraded to Neutral from Buy at Goldman Sachs
- 07/30/21 JPMorgan
- Axcella downgraded to Underweight on lack of catalysts at JPMorgan
- 07/30/21 JPMorgan
- Axcella Health downgraded to Underweight from Neutral at JPMorgan
- 11/03/21 Cantor Fitzgerald
- Clene price target lowered to $15 from $24 at Cantor Fitzgerald
- 11/02/21 Roth Capital
- Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
- 11/02/21 Benchmark
- Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
- 05/20/21 Maxim
- Clene initiated with a Buy at Maxim
- 06/15/21 H.C. Wainwright
- Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
- 02/17/22 Stifel
- Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
- 11/22/21 H.C. Wainwright
- Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
- 11/18/21 Stifel
- Field Trip Health price target raised to C$11.50 from C$10 at Stifel
- 09/01/21 H.C. Wainwright
- Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma - 12/07/21 Maxim
- First Wave BioPharma downgraded to Hold from Buy at Maxim
- 12/07/21 Maxim
- First Wave BioPharma downgraded to Hold from Buy at Maxim
- 10/26/21 Roth Capital
- Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
- 09/29/21 H.C. Wainwright
- H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
- 06/17/21 B. Riley
- Fortress Biotech price target lowered to $8 from $9 at B. Riley
- 04/14/21 B. Riley
- Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
- 02/28/22 Canaccord
- Compass Pathways price target lowered to $78 from $80 at Canaccord
- 11/11/21 Roth Capital
- Atai Life Sciences initiated with a Buy at Roth Capital
- 11/09/21 Citi
- Citi says Compass Pathways selloff overdone, ups price target to $70
- 11/09/21 Cantor Fitzgerald
- Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
- 01/19/22 Brookline
- Dare Bioscience assumed with a Buy at Brookline
- 07/12/21 Roth Capital
- Roth adds more 'SMID-cap' names to second half top picks
- 07/12/21 Roth Capital
- Dare Bioscience NIH agreement should offset costs, says Roth Capital
- 07/07/21 Roth Capital
- Dare Bioscience grant reflects large market need, says Roth Capital
- 12/10/21 H.C. Wainwright
- Delcath Systems initiated with a Buy at H.C. Wainwright
- 06/08/21 Roth Capital
- Delcath Systems data suggest approvability, says Roth Capital
- 04/06/21 Roth Capital
- Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition - 11/12/21
- Fly Intel: Top five analyst upgrades
- 11/12/21 Jefferies
- GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
- 11/12/21 Jefferies
- GlycoMimetics upgraded to Buy from Hold at Jefferies
- 09/27/21 Roth Capital
- GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
- 11/10/21 Roth Capital
- KalVista FDA meeting feedback 'quite positive,' says Roth Capital
- 08/23/21 Roth Capital
- KalVista could take 'substantial' share of HAE market, says Roth Capital
- 04/20/21 Roth Capital
- KalVista selloff seems overdone after clinical hold, says Roth Capital
- 01/31/22 H.C. Wainwright
- KemPharm upgraded to Buy from Neutral at H.C. Wainwright
- 05/26/21 Roth Capital
- Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
- 02/25/22 Barrington
- LeMaitre price target lowered to $54 from $62 at Barrington
- 09/16/21
- Fly Intel: Top five analyst initiations
- 09/16/21 Jefferies
- Jefferies starts LeMaitre at Buy on ArteGraft upside potential
- 09/16/21 Jefferies
- LeMaitre initiated with a Buy at Jefferies
- 02/22/22 Benchmark
- Ligand price target lowered to $130 from $180 at Benchmark
- 02/18/22 Barclays
- Ligand price target lowered to $165 from $185 at Barclays
- 09/22/21 Barclays
- Ligand price target raised to $180 from $174 at Barclays
- 08/25/21 H.C. Wainwright
- Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
- 08/05/21 Piper Sandler
- Lumos shares trading below cash, says Piper Sandler
- 07/22/21 Roth Capital
- Lumos Pharma price target lowered to $35 from $51 at Roth Capital
- 07/21/21 Piper Sandler
- Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
- 07/21/21 H.C. Wainwright
- Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
- 02/17/22 Roth Capital
- Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
- 02/17/22 Piper Sandler
- Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
- 03/25/21 Piper Sandler
- Marker Therapeutics initiated with an Overweight at Piper Sandler
- 03/19/21
- Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics - 02/23/22 Craig-Hallum
- Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
- 06/28/21 Roth Capital
- Panbela Therapeutics initiated with a Buy at Roth Capital
- 01/04/22 William Blair
- P3 Health Partners initiated with an Outperform at William Blair
- 12/28/21 Lake Street
- Lake Street names 18 small cap best ideas for 2022
- $15.75 /
-1.915 (-10.84%) - 03/14/22 Benchmark
- Beauty Health price target raised to $23 from $18 at Benchmark
- 03/11/22 JPMorgan
- Beauty Health initiated with an Overweight at JPMorgan
- 01/07/22 William Blair
- William Blair starts Beauty Health with Outperform, sees 20%-plus growth
- 01/07/22 William Blair
- Beauty Health initiated with an Outperform at William Blair
- 12/01/21 Roth Capital
- Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
- 07/13/21 Roth Capital
- Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
- 04/14/21 Roth Capital
- Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics - 11/01/21 H.C. Wainwright
- Monopar Therapeutics initiated with a Buy at H.C. Wainwright
- 10/19/21 Roth Capital
- Roth Capital bullish on Monopar Therapeutics after competitor trial fails
- 03/02/22 Stifel
- Iridex transferred with Buy rating at Stifel
- 11/02/21 Roth Capital
- iRadimed price target raised to $42 from $36 at Roth Capital
- 01/19/22 Maxim
- INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals - 11/29/21 H.C. Wainwright
- InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics - 01/31/22 H.C. Wainwright
- Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
- 10/19/21
- Fly Intel: Top five analyst upgrades
- 10/19/21 Maxim
- Indaptus Therapeutics upgraded to Buy from Hold at Maxim
- 10/19/21 Maxim
- Indaptus Therapeutics upgraded to Buy from Hold at Maxim
- 11/30/21 Lake Street
- Ensysce Biosciences initiated with a Buy at Lake Street
- 11/11/21 Roth Capital
- aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
- 10/12/21 RBC Capital
- aTyr Pharma initiated with an Outperform at RBC Capital
- 09/21/21 Piper Sandler
- aTyr Pharma initiated with an Overweight at Piper Sandler
- 09/14/21 Oppenheimer
- aTyr Pharma price target raised to $20 from $14 at Oppenheimer
- 11/30/21
- Fly Intel: Top five analyst initiations
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 11/30/21 Maxim
- Atai Life Sciences initiated with a Buy at Maxim
- 11/22/21 Canaccord
- Atai Life Sciences weakness a buying opportunity, says Canaccord
- $15.75 /
-1.915 (-10.84%) - 02/22/22
- Beauty Health sees FY22 revenue $320M-$330M, consensus $314M
- 02/22/22
- Beauty Health reports Q4 EPS (12c), consensus (2c)
- 01/10/22
- Beauty Health sees FY21 revenue $245M -$255M, consensus $231.03M
- 11/09/21
- Beauty Health raises FY21 revenue view to $245M-$255M from $230M-$240M
- 03/09/22
- P3 Health Partners sees 2022 revenue $950M-$1B, consensus $820.04M
- 03/09/22
- P3 Health Partners sees 2021 revenue $642M, consensus $630.57M
- 03/09/22
- P3 Health Partners sees Q4 revenue $183M, consensus $171.07M
- 11/10/21
- Marker Therapeutics reports Q3 EPS (15c), consensus (13c)
MNPR Monopar Therapeutics - 11/12/21
- Monopar Therapeutics reports Q3 EPS (20c), consensus (21c)
- 11/11/21
- Moleculin Biotech reports Q3 EPS (15c), consensus (21c)
- 03/10/22
- Lumos Pharma reports FY21 EPS ($3.65), consensus ($3.89)
- 11/03/21
- Lumos Pharma reports Q3 EPS (90c), consensus ($1.07)
- 02/24/22
- LeMaitre reports Q4 EPS 28c, consensus 31c
- 10/28/21
- LeMaitre sees FY21 EPS $1.26-$1.31, consensus $1.35
- 10/28/21
- LeMaitre sees Q4 EPS 29c-34c, consensus 34c
- 10/28/21
- LeMaitre reports Q3 EPS 30c, consensus 32c
- 03/14/22
- aTyr Pharma reports Q4 EPS (31c), consensus (28c)
- 11/10/21
- aTyr Pharma reports Q3 EPS (42c), consensus (60c)
- 02/17/22
- Ligand sees FY22 revenue $147M-$172M, consensus $189.9M
- 02/17/22
- Ligand reports Q4 EPS $1.80, consensus $1.37
- 11/09/21
- Ligand reaffirms FY21 EPS view $5.80-$6.05, consensus $5.93
- 11/09/21
- Ligand reports Q3 EPS $1.58, consensus $1.04
- 02/03/22
- Lannett lowers FY22 revenue view to $335M-$360M from $370M-$400M
- 02/03/22
- Lannett reports Q2 EPS (39c), consensus (32c)
- 11/03/21
- Lannett cuts FY21 adjusted revenue view $370M-$400M from $400M-$440M
- 11/03/21
- Lannett reports Q1 adjusted EPS (27c), consensus (24c)
- 03/10/22
- KalVista reports Q3 EPS (92c), consensus (93c)
- 12/09/21
- KalVista reports Q2 EPS (80c), consensus (79c)
- 02/04/22
- iRadimed sees 2022 adjusted EPS 91c-$1.01, two est. 83c
- 02/04/22
- iRadimed sees Q1 adjusted EPS 20c-21c
- 02/04/22
- iRadimed reports Q4 adjusted EPS 33c, two est. 21c
- 10/29/21
- iRadimed raises 2021 adjusted EPS view 70c-71c from 60c-62c, two est. 62c
- 01/11/22
- Iridex sees FY21 revenue $53.7M-$53.9M, two estimates $52.64M
- 01/11/22
- Iridex reports preliminary Q4 revenue $15.1M-$15.3M, two estimates $14.01M
- 11/15/21
- INVO Bioscience reports Q3 EPS (24c), two estimates (20c)
INM InMed Pharmaceuticals - 11/10/21
- InMed Pharmaceuticals reports Q1 EPS (25c), one estimate (35c)
- 09/24/21
- InMed Pharmaceuticals reports 2021 EPS ($1.52) vs. ($1.71) last year.
INDP Indaptus Therapeutics - 11/15/21
- Indaptus Therapeutics reports Q3 EPS (81c) vs. (79c) a year ago
- 03/03/22
- GlycoMimetics reports Q4 EPS (33c), consensus (34c)
- 11/02/21
- GlycoMimetics reports Q3 EPS (34c), consensus (32c)
- 02/15/22
- Field Trip Health reports Q3 EPS (26c), consensus (16c)
- 11/15/21
- Field Trip Health reports Q2 EPS (23c), consensus (15c)
- 11/15/21
- Fortress Biotech reports Q3 EPS (26c), consensus (8c)
- 11/09/21
- Delcath Systems reports Q3 EPS (94c), consensus ($1.08)
- 11/10/21
- Dare Bioscience reports Q3 EPS (18c), consensus (13c)
- 11/15/21
- Cocrystal Pharma reports Q3 EPS (4c), consensus (4c)
- 02/24/22
- Compass Pathways reports Q4 EPS (61c), consensus (50c)
- 11/09/21
- Compass Pathways reports Q3 EPS (38c), consensus (49c)
- 03/11/22
- Clene reports 2021 EPS (16c), consensus (17c)
- 11/09/21
- Clene reports Q3 EPS 42c, consensus (20c)
- 11/10/21
- Axcella Health reports Q3 EPS (41c), consensus (46c)
- 11/15/21
- Atai Life Sciences reports Q3 EPS (21c), consensus (20c)
|